Role of Endothelin System and NAD(P)H Oxidase in Retinal Arteriolar Dysfunction

内皮素系统和 NAD(P)H 氧化酶在视网膜小动脉功能障碍中的作用

• 批准号: 8005501
• 负责人: TRAVIS W HEIN
• 金额: $ 31.64万
• 依托单位: TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8005501
• 关键词: Accounting; Acetylcholine; Acute; Address; Affect; Agonist; Angle-Closure Glaucoma; Animals; Attention; Big Endothelin; Biochemical; Biological Availability; Blindness; Blood Vessels; Blood flow; Bradykinin; Brain; Caliber; Chemicals; Clinical; Clinical Treatment; Complex; Critiques; Data; Development; Diabetic Retinopathy; Disadvantaged; Disease; Effectiveness; Endothelin; Endothelin B Receptor; Endothelin Receptor; Endothelin-1; Endothelin-converting enzyme 1; Endothelium; Enzyme Inhibitor Drugs; Enzyme Inhibitors; Event; Eye; Family suidae; Fluorescein Angiography; Free Radicals; Functional disorder; Fundus photography; Future; Goals; Heart; Hour; Impairment; In Vitro; Injection of therapeutic agent; Injury; Ischemia; Lead; Link; MAPK14 gene; Measurement; Measures; Mediating; Metabolism; Methods; Microcirculation; Mitogen-Activated Protein Kinases; Modality; Modeling; Molecular; Neuroglia; Neurons; Nitric Oxide; Operative Surgical Procedures; Oxidases; Oxidative Stress; Oxygen; Paired Comparison; Pathogenesis; Pathway interactions; Perfusion; Physiologic Intraocular Pressure; Physiological; Pilot Projects; Prevention; Principal Investigator; Procedures; Process; Production; Protein Kinase; Protein Kinase C; Proteins; Protocols documentation; Published Comment; Reactive Oxygen Species; Regulation; Relative (related person); Research Design; Retina; Retinal; Retinal Diseases; Retinal Vascular Occlusion; Retinopathy of Prematurity; Rho-associated kinase; Role; Sample Size; Series; Signal Pathway; Signal Transduction; Site; Smooth Muscle; Source; Specificity; Stress; Superoxides; System; Techniques; Testing; Therapeutic Intervention; Thiorphan; Time; Tissue Survival; Tissues; Vascular Diseases; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents; Vasomotor; Visual impairment; Work; arteriole; base; central retinal artery; constriction; endothelin-converting enzyme; human MAPK14 protein; in vivo; inhibitor/antagonist; insight; interest; neuronal survival; novel; phosphoramidon; premature; prevent; programs; receptor; relating to nervous system; research study; response; retina blood vessel structure; retinal damage; retinal ischemia; rho; therapy development; vasoconstriction

DESCRIPTION (provided by applicant): Acute periods of retinal ischemia impair subsequent supply of retinal blood flow and have been associated with several ocular diseases leading to visual impairment and blindness. Experimental evidence of diminished retinal blood flow after the initial retinal ischemia suggests that endothelial dysfunction may contribute to persistent retinal damage. Two important endothelium-derived factors involved in regulating retinal blood flow are vasodilator nitric oxide (NO) and vasoconstrictor endothelin-1 (ET-1). Our preliminary studies showed that retinal ischemia via elevated intraocular pressure (IOP) impaired bradykinin-induced NO-mediated dilation and enhanced ET-1-mediated constriction in pig retinal arterioles. Intravitreal administration of superoxide scavenger TEMPOL or endothelin-converting enzyme (ECE) inhibitor phosphoramidon before ischemia preserved vasodilation to bradykinin. Although these pilot studies suggest the involvement of ET-1 and oxidative stress in vascular dysfunction, their interrelationship and the signaling events contributing to the observed impairment remain to be elucidated. Herein, we hypothesize that ischemic insult activates the protein kinase C (PKC)-dependent vascular endothelin system, which leads to superoxide production via NAD(P)H oxidase and a subsequent increase in Rho/Rho kinase activation for the increased vascular tone and a reduced NO-mediated vasodilation. Since our long-term goal is to understand the signaling mechanisms responsible for physiological and pathophysiological regulation of retinal vasomotor function leading to future vascular therapy, the present application will serve the initial step toward this goal by identifying the causal factor and cellular mechanisms contributing to the impairment of vascular function following acute retinal ischemia. We will test the aforementioned hypothesis by pursuing three specific aims: (1) Determine whether enhanced ECE and PKC activities contribute to ischemia-induced dysfunction of retinal arterioles. (2) Determine whether activation of endothelin A/B receptors and vascular p38 mitogen-activated protein kinase/NAD(P)H oxidase signaling contributes to ischemia-induced dysfunction of retinal arterioles. (3) Determine whether enhanced vascular Rho/Rho kinase signaling contributes to ischemia-induced dysfunction of retinal arterioles. We will use both in-vivo and in-vitro approaches with various cellular/molecular techniques to integrate these three aims for elucidating the underlying mechanisms and signaling pathways responsible for the ischemia-induced arteriolar dysfunction in the retina. The results derived from these studies are essential to advance our understanding in the pathogenesis of retinal vascular disease associated with retinal ischemia and may suggest novel targets for future therapeutic interventions. Reduction in normal blood flow or ischemia to the retina in the eye has been associated with several ocular diseases leading to visual impairment and blindness. Experimental evidence of diminished retinal blood flow after the initial retinal ischemia suggests that reduction in the ability of small blood vessels, the arterioles, to widen or dilate by producing or responding to the chemical nitric oxide may contribute to persistent damage of the retina. A potential mechanism leading to the impairment of blood vessel function is elevated levels of endothelin in the retina. Endothelin is a protein that can impact blood vessels by causing them to collapse or constrict, or by increasing the production of oxygen-derived free radicals, which can damage nitric oxide. However, the precise roles of and potential link between these two events in contributing to this abnormal function of retinal vessels following retinal ischemia remain unknown. The goal of this proposal is to gain a better understanding into the mechanisms leading to the functional damage of the small blood vessels in the retina, which will be helpful for development of new therapies for retinal ischemic disease.

描述（由申请人提供）：急性期视网膜缺血损害随后的视网膜血流供应，并与几种导致视力损害和失明的眼部疾病有关。初始视网膜缺血后视网膜血流减少的实验证据表明，内皮功能障碍可能导致持续的视网膜损伤。参与调节视网膜血流的两个重要内皮源性因子是血管舒张剂一氧化氮（NO）和血管收缩剂内皮素-1 （ET-1）。我们的初步研究表明，眼压升高引起的视网膜缺血损害了缓激肽诱导的no介导的扩张和et -1介导的猪视网膜小动脉收缩。缺血前玻璃体内给予超氧化物清除剂TEMPOL或内皮素转换酶（ECE）抑制剂磷酰胺可维持血管舒张。尽管这些初步研究表明ET-1和氧化应激参与血管功能障碍，但它们之间的相互关系以及导致观察到的损伤的信号事件仍有待阐明。在此，我们假设缺血损伤激活了蛋白激酶C （PKC）依赖的血管内皮素系统，通过NAD(P)H氧化酶导致超氧化物的产生，随后Rho/Rho激酶激活增加，从而增加血管张力和减少no介导的血管舒张。由于我们的长期目标是了解视网膜血管舒缩功能的生理和病理生理调节的信号机制，从而导致未来的血管治疗，目前的应用将通过确定导致急性视网膜缺血后血管功能损伤的原因和细胞机制，为实现这一目标迈出第一步。我们将通过三个具体目标来检验上述假设：(1)确定ECE和PKC活性增强是否有助于缺血性视网膜小动脉功能障碍。(2)确定内皮素A/B受体和血管p38丝裂原活化蛋白激酶/NAD(P)H氧化酶信号的激活是否与视网膜小动脉缺血功能障碍有关。(3)确定血管Rho/Rho激酶信号的增强是否与视网膜小动脉缺血引起的功能障碍有关。我们将使用体内和体外方法，结合各种细胞/分子技术来整合这三个目标，以阐明视网膜缺血诱导的小动脉功能障碍的潜在机制和信号通路。这些研究的结果对于促进我们对视网膜缺血相关视网膜血管疾病发病机制的理解至关重要，并可能为未来的治疗干预提供新的靶点。正常血流减少或视网膜缺血与几种眼部疾病有关，可导致视力损害和失明。初始视网膜缺血后视网膜血流量减少的实验证据表明，小血管（小动脉）通过产生或响应化学一氧化氮而扩大或扩张的能力降低可能导致视网膜的持续损伤。导致血管功能受损的潜在机制是视网膜内皮素水平升高。内皮素是一种可以影响血管的蛋白质，它可以导致血管塌陷或收缩，或者增加氧源性自由基的产生，而氧源性自由基会破坏一氧化氮。然而，这两个事件在视网膜缺血后视网膜血管功能异常中的确切作用和潜在联系尚不清楚。本课题旨在更好地了解视网膜小血管功能损伤的机制，为视网膜缺血性疾病的新疗法的开发提供帮助。